MIR-21-5P DRIVES NASH-ASSOCIATED HEPATOCARCINOGENESIS

Pedro M. Rodrigues  ^{1, 2, 3}     Marta Bento Afonso  ³     André Lopes Simão  ³     Tawhidul Islam  ³     Maria Manuela Gaspar  ³     Colm J. O’Rourke  ⁴     Monika Lewinska  ⁴     Jesper B. Andersen  ⁴     Enara Arretxe  ⁵     Cristina Alonso  ⁵     Álvaro Santos-Laso  ⁵     Laura Izquierdo-Sanchez  ^{1, 2}     Raúl Jimenez-Agüero  ²     Emma Eizaguirre  ²     Luis Bujanda  ^{2, 6}     Maria J. Pareja  ⁷     Carina Prip-Buus  ⁸     Jesús M. Bañales  ^{2, 6, 9}     Cecília Maria Pereira Rodrigues  ⁹     Rui Castro  ^9    
1 Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal
² Donostia University Hospital, University of the Basque Country (UPV/EHU), San Sebastian, Spain
³ Centre for the Study of Liver and Gastro
⁴ Biotech Research and Innovation Centre, Department of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
⁵ OWL Metabolomics, Derio, Spain
⁶ Centre for the Study of Liver and Gastrointestinal Diseases (CIBERehd), Carlos III National Institute of Health, Madrid, Spain
⁷ Hospital Juan Ramón Jiménez, Huelva, Spain
⁸ Université Paris Descartes UMR-S 1016, Institut Cochin, Paris, France
⁹ IKERBASQUE, Basque Found

Topic
Colorectal, Digestive Oncology, Hepatobiliary, Mechanisms & Personalised Medicine, Pancreas

Session
Carcinogenesis revisited

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)